3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
3
Desmoid Tumors
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Disease
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Unresectable Solid Tumors
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Respiratory Aspiration
1
Pancreatic Adenocarcinoma Locally Advanced
1
Neuroma
1
Neuralgia
1
Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypesthesia
1
High-Burden Metastatic Solid Tumors
1
Interventions
Oxaliplatin
19
pembrolizumab
13
Fluorouracil
12
Leucovorin
11
Capecitabine
11
Paclitaxel
10
Gemcitabine
8
Docetaxel
8
zolbetuximab
6
cemiplimab
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
durvalumab
5
Ramucirumab
5
Radiotherapy
5
Irinotecan
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
trastuzumab deruxtecan
3
tislelizumab
3
lenvatinib
3
enzalutamide
3
darolutamide
3
Trastuzumab
3
Taxes
3
S 1 (combination)
3
Radiosurgery
3
Pemetrexed
3
Nivolumab
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Cryosurgery
×
1 year
×
Clear all
NCT07237399
2026-05-13
TA-P-OLIM
University Hospital, Ghent
Withdrawn